Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2466
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy ; volume:19 ; number:1 ; day:22 ; month:8 ; year:2019 ; pages:1-9 ; date:12.2019
BMC pulmonary medicine ; 19, Heft 1 (22.8.2019), 1-9, 12.2019

Urheber
Tahara, Masahiro
Oda, Keishi
Yamasaki, Kei
Kawaguchi, Takako
Sennari, Konomi
Noguchi, Shingo
Sakamoto, Noriho
Kawanami, Toshinori
Mukae, Hiroshi
Yatera, Kazuhiro
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12890-019-0918-3
URN
urn:nbn:de:101:1-2020010523000308558118
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
05.02.20251, 15:41 MEZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Tahara, Masahiro
  • Oda, Keishi
  • Yamasaki, Kei
  • Kawaguchi, Takako
  • Sennari, Konomi
  • Noguchi, Shingo
  • Sakamoto, Noriho
  • Kawanami, Toshinori
  • Mukae, Hiroshi
  • Yatera, Kazuhiro
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Verbundene Objekte